Cargando…
Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab
Hypereosinophilic syndrome (HES) is characterized by a persistently elevated eosinophil count associated with eosinophil-related end-organ damage and thromboembolic events, in the absence of an identifiable cause. We present a case of idiopathic HES with evidence of peripheral and tissue eosinophili...
Autores principales: | Kay, Dana, Ataya, Ali, Liu, Xiuli, Auerbach, Jena, Urbine, Dan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038714/ https://www.ncbi.nlm.nih.gov/pubmed/29998055 http://dx.doi.org/10.1016/j.rmcr.2018.05.013 |
Ejemplares similares
-
Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone
por: Lachance, Madeleine, et al.
Publicado: (2022) -
Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
por: Fujii, Koki, et al.
Publicado: (2020) -
Mepolizumab in Hypereosinophilic Syndrome: A Systematic Review and Meta-analysis
por: Alves, José Mario, et al.
Publicado: (2021) -
Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome
por: Pane, Fabrizio, et al.
Publicado: (2022) -
Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome
por: Reiter, Andreas, et al.
Publicado: (2022)